SecBot SecBot
8-K ·Filed Nov 9, 2026

IBRX

ImmunityBio, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 17h ago SEC0001326110-26-000091
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

Monitor the sBLA submission by year-end 2026 and FDA acceptance/priority review decision. Full study details at an upcoming medical congress may provide additional efficacy and durability data. The expanded addressable population (BCG-naive) represents a much larger market than the current BCG-unresponsive indication.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$7.11
T+0 close · Nov 9, 2026 · via day close
Latest settled
−15.89%
T+5 · $5.98
Vs SPY
−14.20%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $7.11entry
  2. T+1 · 7d ago −5.13%α −4.77% · $6.75
  3. T+5 · 17h ago −15.89%α −14.20% · $5.98
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio announced positive final analysis results from the QUILT-2.005 trial, showing ANKTIVA plus BCG met the primary efficacy endpoint in BCG-naive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ. The chemotherapy-free combination demonstrated a statistically significant improvement over BCG alone. A supplemental BLA submission to the FDA remains on track for year-end 2026, potentially expanding ANKTIVA's approved indication to earlier-stage patients.

Key Facts

  • ANKTIVA plus BCG met the primary efficacy endpoint in Cohort A of the randomized registrational QUILT-2.005 trial in BCG-naive NMIBC patients with CIS
  • The combination demonstrated a statistically significant improvement in efficacy compared with BCG alone
  • Trial enrolled 370 randomized patients across over 75 clinical trial sites
  • Database lock occurred on October 20, 2026
  • Supplemental BLA submission to FDA remains on track for year-end 2026
  • No treatment-related deaths were reported; safety profile consistent with BCG alone
  • Median duration of response had not yet been reached with ANKTIVA plus BCG
  • ANKTIVA was previously approved in April 2024 for BCG-unresponsive NMIBC CIS, with indication expanded in October 2026

Financial Impact

Positive Phase 3 readout for a registrational trial in a larger addressable patient population (BCG-naive vs. BCG-unresponsive) could significantly expand ANKTIVA's commercial opportunity, though no financial figures were disclosed

revenue

Risk Factors

  • sBLA submission or FDA review may be delayed or result in a non-approval decision
  • Open-label trial design may introduce bias; final results could change with longer follow-up
  • Competition from existing and future therapies for BCG-naive NMIBC
  • Manufacturing and supply risks, including BCG availability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326110-26-000091
Document: ibrx-20261109.htm0001326110-26-000091
Document: 0001326110-26-000091-index-headers.html0001326110-26-000091
Document: 0001326110-26-000091-index.html0001326110-26-000091
Document: 0001326110-26-000091.txt0001326110-26-000091

Track record

11 reports on IBRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $7.11 Now $5.98 −15.89% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
  4. Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
  5. Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
  6. Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
  7. Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
  8. May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
  9. Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
  10. Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (9h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026